Filing Flows › Lipocine (LPCN) › Q2 2026 › vs Q1 2026
Lipocine (LPCN) Q2 2026 vs Q1 2026 (quarter over quarter)
Lipocine's revenue rose $71K (+59%) from $119K in Q1 2026 to $190K in Q2 2026.
Lipocine, Q2 2026: revenue $190K (-70% year over year), net loss $2.6M, operating cash flow −$3.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $190K | $119K | $71K | +59% |
| Other income, net | $220K | $178K | $42K | +24% |
| Net loss | $2.6M | $3.7M | −$1.0M | -29% |
| Costs & expenses | $3.0M | $4.0M | −$936K | -24% |
| Operating costs | $3.0M | $4.0M | −$937K | -24% |
| Income tax | $200 | $0 | $200 | — |
| Research & development | $2.0M | $2.8M | −$723K | -26% |
| General & admin | $991K | $1.2M | −$214K | -18% |
| Operating cash sources | $3.1M | $2.3M | $764K | +33% |
| Depreciation & amortization | $15K | $15K | −$166 | -1% |
| Share-based compensation | $58K | $65K | −$7K | -11% |
| Cash used in operations | $3.0M | $2.3M | $771K | +34% |
| Net loss absorbed | $2.6M | $3.7M | −$1.0M | -29% |
| Working capital & other | $479K | −$1.3M | $1.8M | — |
Questions
How much did Lipocine's revenue grow quarter over quarter in Q2 2026?
Lipocine's revenue rose $71K (+59%) from $119K in Q1 2026 to $190K in Q2 2026.